Physician profile
Sharon E Orrange
NPI 1316983406
$1,777.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2021: $588 · 2022: $1,066 · 2023: $14.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.57 | 2019-2023 | Ozempic, Tresiba, Rybelsus |
| Lilly USA, LLC | $292.56 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $232.90 | 2022 | |
| Abbvie INC. | $111.74 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.48 | 2021-2022 | |
| Eisai INC. | $38.53 | 2021-2022 | |
| Becton, Dickinson and Company | $38.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $33.31 | 2021 | |
| Tandem Diabetes Care, INC. | $28.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.55 | 2019 | |
| Zealand Pharma US, INC. | $21.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Orrange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.